301. Macular dystrophy Clinical trials / Disease details
Clinical trials : 46 / Drugs : 42 - (DrugBank : 11) / Drug target genes : 9 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00346853 (ClinicalTrials.gov) | November 2005 | 28/6/2006 | Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy | Clinical Interventions Against Stargardt Macular Dystrophy: Phase 1 Pilot Study of 4-MP as an Inhibitor of Dark Adaptation | Macular Dystrophy, Corneal | Drug: 4-Methylpyrazole;Other: saline | University of Utah | NULL | Completed | 18 Years | 65 Years | All | 10 | Phase 1 | United States |